• Explore /
  • Poster
  • / Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), <em>PIK3CA</em>-mutated advanced breast cancer (ABC) from BYLieve.

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.

Abstract Video & Slides Poster

Authors

null

Stephen K. L. Chia

British Columbia Cancer Agency, Vancouver, BC, Canada

Stephen K. L. Chia , Manuel Ruiz-Borrego , Pamela Drullinsky , Dejan Juric , Thomas Bachelot , Hope S. Rugo , Eva M. Ciruelos , Florence Lerebours , Aleix Prat , Murat Akdere , Christina Arce , Ennan Gu , Nicholas C. Turner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT03056755

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1060)

DOI

10.1200/JCO.2021.39.15_suppl.1060

Abstract #

1060

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Hope S. Rugo

First Author: Dejan Juric

First Author: Stephen Chia

First Author: Emily J. Gallagher